Contribute Try STAT+ Today

Peter Adamson joined Sanofi in late March, as the coronavirus pandemic surged around the world and changed lives and livelihoods. Someday, he says, he’ll take up his new role in Cambridge, Mass., as global development therapeutic area head for oncology in general and pediatric innovation in particular, but for now he is leading and learning from his home in South Jersey.

A pediatric oncologist, Adamson spent the last 30 years caring for children and doing cancer research. He was a professor of pediatrics and pharmacology at the Perelman School of Medicine at the University of Pennsylvania and at the Children’s Hospital of Pennsylvania (CHOP). For the past 10 years, he chaired the Children’s Oncology Group, an international consortium supported by the National Cancer Institute whose 230 members carry out translational research and large-scale clinical trials in children and adolescents with cancer. 

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.